OneDigital Investment Advisors LLC Has $2.15 Million Holdings in Stryker Corporation $SYK

OneDigital Investment Advisors LLC cut its position in Stryker Corporation (NYSE:SYK) by 59.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,807 shares of the medical technology company’s stock after selling 8,594 shares during the quarter. OneDigital Investment Advisors LLC’s holdings in Stryker were worth $2,147,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in SYK. Clayton Financial Group LLC bought a new position in shares of Stryker in the 3rd quarter valued at about $26,000. Elevation Point Wealth Partners LLC acquired a new stake in Stryker in the 2nd quarter valued at about $28,000. Kilter Group LLC bought a new position in Stryker during the second quarter worth about $29,000. Howard Hughes Medical Institute bought a new position in Stryker during the second quarter worth about $29,000. Finally, ANTIPODES PARTNERS Ltd acquired a new position in Stryker during the third quarter worth approximately $34,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts recently weighed in on the company. TD Cowen lowered Stryker from a “buy” rating to a “hold” rating and set a $387.00 target price on the stock. in a report on Monday, January 26th. Needham & Company LLC upped their price objective on shares of Stryker from $448.00 to $454.00 and gave the company a “buy” rating in a report on Friday, January 30th. Sanford C. Bernstein increased their price objective on shares of Stryker from $450.00 to $465.00 and gave the company an “outperform” rating in a research report on Friday, January 9th. Evercore set a $390.00 target price on shares of Stryker in a report on Monday, January 5th. Finally, BTIG Research increased their price target on shares of Stryker from $410.00 to $412.00 and gave the company a “buy” rating in a report on Friday, January 30th. Thirteen investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Stryker currently has an average rating of “Moderate Buy” and a consensus price target of $426.47.

Stryker Price Performance

NYSE:SYK opened at $381.84 on Wednesday. Stryker Corporation has a 52 week low of $329.16 and a 52 week high of $404.87. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.21 and a current ratio of 1.89. The firm’s 50-day simple moving average is $361.24 and its 200 day simple moving average is $368.91. The firm has a market cap of $146.13 billion, a price-to-earnings ratio of 45.46, a P/E/G ratio of 2.25 and a beta of 0.87.

Stryker (NYSE:SYK) last announced its earnings results on Thursday, January 29th. The medical technology company reported $4.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.40 by $0.07. Stryker had a net margin of 12.92% and a return on equity of 24.41%. The firm had revenue of $7.17 billion for the quarter, compared to analyst estimates of $7.12 billion. During the same quarter in the prior year, the business posted $4.01 EPS. The business’s revenue was up 11.4% compared to the same quarter last year. As a group, sell-side analysts predict that Stryker Corporation will post 13.47 earnings per share for the current year.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, April 30th. Shareholders of record on Tuesday, March 31st will be paid a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date is Tuesday, March 31st. Stryker’s dividend payout ratio (DPR) is 41.90%.

Insider Buying and Selling at Stryker

In other news, Director Ronda E. Stryker sold 250,000 shares of the company’s stock in a transaction on Wednesday, February 4th. The stock was sold at an average price of $362.92, for a total transaction of $90,730,000.00. Following the completion of the sale, the director directly owned 2,457,331 shares in the company, valued at approximately $891,814,566.52. This represents a 9.23% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 5.20% of the company’s stock.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.